The present invention provides methods for treatment of volume-dependent Acute Kidney Injury (vAKI) and ischemic Acute Kidney Injury (iAKI), as well as methods for diagnosing vAKI and iAKI. The methods are based on determining the levels of PAPPA2, NGAL, KRT20, or TAC-STD2 protein in a sample from a patient, such as a urine sample. The present invention also provides a device and a diagnostics kit for determining whether a sample from a subject contains PAPPA2, NGAL, KRT20, or TACSTD2 protein.

The present disclosure relates to methods and compositions for detecting mitochondrial dysfunction. In particular, the disclosure relates to reporter molecules that are cleavable by the zinc metalloprotease Metalloendopeptidase OMA1 (OMA1). In each embodiment, the reporter molecules of the invention are particularly useful for drug discovery and detection of diseases associated with mitochondrial dysfunction

The invention relates to recombinant nucleic acid and polypeptides encoding collagenase I and collagenase II, methods for the preparation thereof and methods for the use thereof. The invention also encompasses methods related to releasing a composition comprising collagenase prior to therapeutic administration.

Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, ?1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin. The present invention has the advantages of being simple and rapid, flexible in sample preparation, low in limit of detection, good in repeatability and high in sensitivity; and the sample preparation and detection method is simple and easy to implement, low in cost and suitable for popularization and use.

The present invention provides a data analytic scheme for screening biomarkers for differential diagnosis of the status of Parkinson's disease, Parkinson's disease with mild cognitive impairment, Parkinson's disease dementia, Alzheimer's disease, and/or multiple system atrophy, the methodology implementing the same and the results of the screening thereof. Biomedical Oriented Logistic Dantzig Selector (BOLD Selector) was developed to identify candidate microRNAs and extracellular vesicle proteins effective at discerning between any two of the above mentioned disease categories from profiling results. The prediction models are finalized by establishing logistic regression formula for each pair of patient group differentiation.

A method for collecting information about the health status of a subject involving the quantitative detection, in serum, plasma or blood of the subject, of the concentration of at least four of the systems selected from the group consisting of: THBS1, LUM, FN1, LG3BP, MMP9, as well as PSA.

A method of bioassay for the quantification of peptide fragments elevated in lung diseases such as COPD, SCC, or IPF, comprising a neo-epitope formed at a cleavage site by cleavage in vivo of elastin by a proteinase by contacting a sample with an antibody having specific binding affinity for a the neo-epitope amino acid sequence and determining the level of binding, where the antibody binds one of the following terminal sequences:

TABLE-US-00001 ...FGPGVV ...VPGLGV IKAPKL...
and antibodies and immunoassay kits for use in such methods.

A biocompatible SERS-active polymer membrane configured to detect biomarkers in a sample. The biocompatible SERS-active polymer membrane includes a flexible and porous polymer membrane and SERS-active nanoparticles formed on the flexible and porous polymer membrane, where the flexible and porous polymer membrane includes cellulose or an elastomeric polymer. Also disclosed herein is a method of forming the biocompatible SERS-active polymer membrane and a method of determining a state of wound healing in a diabetic individual involving the use of the biocompatible SERS-active polymer membrane.

The present invention relates to agonists of Neprilysin and their use in preventing and treating pulmonary vascular remodeling. Also described are diagnostic and screening applications stemming from the inventor's discovery that Neprilysin is expressed at reduced levels in disease tissues.

A method of diagnosing metastatic potential of a breast cancer in an individual with breast cancer is described. The method comprises a step of assaying a breast cancer tumor sample from the patient for expression of A Disintegrin And Metalloproteinase 22, (ADAM22), wherein expression of ADAM22 correlates with increased potential for metastasis compared with a patient who is ADAM22 negative. The invention also describes an agent for use in the treatment of metastatic breast cancer in a patient, in which the agent is selected from leucine-rich, glioma-inactivated protein 1 (LGI1) protein (SEQ ID NO:1) and an LGI1 peptide mimic capable of mimicking the ADAM22 binding activity of LGI1 by binding to the LGI1 binding domain of ADAM22 (SEQ ID NO: 4) and which is capable of inhibiting migration of endocrine resistant breast cancer cells.